Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Allisartan isoproxil + amlodipine is a fixed-dose combination tablet containing two antihypertensive agents: allisartan isoproxil (an angiotensin II type 1 receptor blocker, ARB) and amlodipine (a calcium channel blocker, CCB). This combination is indicated for the treatment of essential hypertension in adults whose blood pressure is not adequately controlled by either agent alone. Allisartan isoproxil acts as a prodrug that converts to its active metabolite EXP3174 after oral administration; this metabolite selectively blocks the angiotensin II type 1 receptor (AT1R), reducing vascular resistance and blood pressure. Amlodipine inhibits L-type calcium channels in vascular smooth muscle, leading to vasodilation and further lowering of blood pressure. The product was developed as an original domestic compound preparation in China by Shenzhen Salubris Pharmaceuticals for improved efficacy in patients with poor response to monotherapy[1][5][6][8].
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on allisartan isoproxil + amlodipine.